Toggle light / dark theme

Nearly 500 years ago in what we now call Mexico, a disease started rippling through the population. Red spots appeared on the skin, accompanied by wretched vomiting, bleeding from multiple orifices, and eventually, death. Combined with an invasion from Europe and horrific droughts, it was generally not a pleasant time or place to be alive.

It bore the name cocoliztli, meaning ‘pestilence,’ and it killed between five and 15 million people in just three years. As many plagues were at the time, it proved deadly and mysterious, burning through entire populations. Occurring centuries before John Snow’s work on cholera gave rise to epidemiology, data on the disease’s devastation was sparse. Over the years, researchers and historians attempted to pin the blame for the illness on measles, plague, viral hemorrhagic fevers like Ebola, and typhoid fever—a disease caused by a variation of the bacteria Salmonella enterica.

In a paper published this week in Nature Ecology & Evolution, researchers present evidence that the latter was the most likely candidate in this cast of microbial miscreants. The study was pre-printed in biorxiv last year. The researchers detected the genome of a different variety of Salmonella enterica (the specific variety is Paratyphi C) in teeth of individuals buried in a cemetery historically linked to the deadly outbreak.

Read more

But it remains to be seen whether drug regulators will go along with a new way of making medicines. To do so, agencies like the U.S. Food and Drug Administration will need to rewrite their rules for validating the safety of medicines. Instead of signing off on the production facility and manufactured drug samples, regulators would have to validate that reactionware produces the desired medication. Cronin agrees it’s a hurdle. But he argues that future printed reactors could simply include a final module containing standard validation tests that produce a visual readout, much like a pregnancy test. “I think it’s manageable.”


Digitized chemistry on demand could also undermine drug counterfeiters.

Read more

Looking back at best of 2017)


The finding was a milestone in the field of anti-aging science. Professor Judith Campisi, Ph.D., a celebrity in the anti-aging field, and lead author of the study remarked

“Imagine the possibility of taking a pill [rapamycin] for a few days or weeks every few years, as opposed to taking something with side effects every day for the rest of your life. It’s a new way of looking at how we could deal with age-related maladies.” – Judith Campisi, PhD

Campisi’s discovery suggests that a person could take rapamycin intermittently, say, once a week, shutting down the chronic inflammation. Because the zombie cells haven’t gone away, they will eventually find their footing and start the inflammatory ball rolling once again. A person on this regimen would repeat the dosage intermittently and substantially reduce inflammation.

Looking back at best of 2017)


Summary: Nanotechnology meets gene editing. MIT researchers use nanoparticles instead of viruses to deliver the CRISPR gene editing system. This article first appeared on LongevityFacts. Author: Brady Hartman]

In a new study, MIT scientists have developed nanoparticles that deliver the CRISPR gene editing system, eliminating the need to use viruses for delivery.

Using the new delivery technique, the gene editors were able to cut out genes in about 80 percent of liver cells, the best success rate ever achieved with CRISPR in adult animals. Speaking about the success of the project, Daniel Anderson, senior author of the study and an associate professor in MIT’s Department of Chemical Engineering, said.

If you were awestruck by the New Year’s Day super moon, hold onto your pants.

On January 31, around midnight, the full moon will not only be super, it will be a blue moon and a blood moon.

The blue moon comes as it will be the second full moon in a month. That happens every two and a half years, hence the saying “once in a blue moon”.

Read more